Clinical studies with MTA
1998

Clinical Studies with MTA

Sample size: 37 publication Evidence: moderate

Author Information

Author(s): AH Calvert, JM Walling

Primary Institution: Division of Oncology, Newcastle General Hospital

Hypothesis

It is not known whether the anti-tumour activity of MTA depends on its TS inhibition or whether other loci contribute.

Conclusion

MTA appears to show promising activity in the treatment of several solid tumours, including breast, colorectal, pancreas, and NSCL cancers.

Supporting Evidence

  • MTA has been shown to have activity against a range of human cell lines, including colon, renal, hepatoma, and lung cancer.
  • Preliminary phase II trials results are encouraging; responses were seen in colorectal, pancreas, NSCLC, and breast cancer.
  • Phase II trials are being carried out in patients with solid tumours, particularly cancers of the breast and pancreas.

Takeaway

MTA is a new medicine that helps fight cancer by blocking certain enzymes, and it seems to work well for different types of cancer.

Methodology

MTA was examined in three phase I trials using different schedules: a 10-min i.v. infusion given once every 3 weeks, once weekly for 4 weeks every 6 weeks, or daily for 5 days every 3 weeks.

Limitations

The phase II results are preliminary and further data are required before conclusions can be drawn regarding the absolute efficacy.

Participant Demographics

{"male":27,"female":10,"age_range":"30-74","median_age":59}

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication